| 0.7199 Data as of May 24 |  +0.0199 / +2.84%Today’s Change | 0.63 Today|||52-Week Range 2.78 | -46.28% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $9.1M |
Company Description
GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. It is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. Its development programs address therapeutic areas such as hearing loss, balance disorders and cancer; as well as vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus type 2, dengue fever, influenza, malaria and human immunodeficiency virus. The company's research and development activities yield product candidates that utilize its technology platform and it believe represent potential commercial opportunities. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.
Employees
Shareholders
| Mutual fund holders | 2.31% |
| Other institutional | 12.88% |
| Individual stakeholders | 0.83% |
Top Executives
| Cynthia L. Collins, MBA | President, Chief Executive Officer & Director |
| Douglas J. Swirsky, MBA, CPA | CFO, Secretary, Treasurer & Senior Vice President |
| Douglas E. Brough, PhD | Vice President-Research |
| Marge M. Meyer | Executive Director-Human Resources |
| Bryan T. Butman, PhD | Senior Vice President-Vector Operations |
.
